Quantib B.V. has received approval from U.S. and European regulators to market its first product, Quantib Brain 1.1 in their jurisdictions. The company received European Union CE marking and clearance from the U.S. Food and Drug Administration for its advanced analytical software. Quantib Brain 1.1 automatically extracts biomarkers from brain MRI scans. Such neurobiomarkers are strongly correlated with the onset and development of neurodegenerative and inflammatory diseases such as Alzheimer's and multiple sclerosis. press release [pfd]